VLRX News

Two IPOs diverged in trading this week. Alteryx was fairly well-received by investors, popping 11% on its first day of trading Friday. Valeritas, which had failed to IPO in 2015, broke issue despite insiders purchasing 67% of the deal. The average 2017 IPO is up 12% and 64% are trading above their IPO price. ...read more

Valeritas Holdings, which markets a disposable device that delivers insulin therapy for Type 2 diabetes, raised $53 million by offering 5.3 million shares at $10, within the range of $9 to $11. Valeritas Holdings plans to list on the Nasdaq under the symbol VLRX. Cowen & Company and Wedbush PacGrow acted as lead managers on the deal....read more

After Snap (SNAP) had a historic multi-billion IPO, high-growth software provider MuleSoft (MULE) followed up with the best first day of the year this past week, closing Friday up 46%. Alteryx (AYX) is the only IPO with a set date for next week as it will continue to feed investors' appetites for enterprise software companies...read more

Valeritas Holdings, which markets a disposable device that delivers basal-bolus insulin therapy for Type 2 diabetes, announced terms for its IPO on Thursday. The Bridgewater, NJ-based company plans to raise $60 million by offering 6.0 million shares at a price range of $9 to $11. Insiders intend to purchase $40 million worth of shares in the offering. At the midpoint of the...read more